Tag:
Diabetes Drug
Latest Headlines
Latest Headlines
Lilly, Amylin win NICE nod for Bydureon
The U.K.'s cost-effectiveness watchdog is feeling friendly toward Eli Lilly's ( $LLY ) long-acting diabetes drug Bydureon. The National Institute for Health and Clinical Excellence recommended the
